drug administration fda approval Search Results


food and drug administration fda  (Biomol GmbH)
90
Biomol GmbH food and drug administration fda
Food And Drug Administration Fda, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration+fda/10__2147_slash_dddt__s101486-43-35-32
Average 90 stars, based on 1 article reviews
food and drug administration fda - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
food and drug administration (fda)-approved concentration assay plac  (diaDexus Inc)
90
diaDexus Inc food and drug administration (fda)-approved concentration assay plac
Food And Drug Administration (Fda) Approved Concentration Assay Plac, supplied by diaDexus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration++fda++approved+concentration+assay+plac/pm29321128-17-11-17
Average 90 stars, based on 1 article reviews
food and drug administration (fda)-approved concentration assay plac - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
fda food and drug administration  (Clinical and Laboratory Standards Institute)
90
Clinical and Laboratory Standards Institute fda food and drug administration
Fda Food And Drug Administration, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/fda+food+and+drug+administration/pmc02901024-127-9-1
Average 90 stars, based on 1 article reviews
fda food and drug administration - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
standard clinical pet platform siemens syngo.via  (Siemens AG)
90
Siemens AG standard clinical pet platform siemens syngo.via
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Standard Clinical Pet Platform Siemens Syngo.Via, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration++fda++approved+medical+workstation+leonardo+version+syngo+mmwp+ve20a+sl08862/pmc08195345-70-35-38
Average 90 stars, based on 1 article reviews
standard clinical pet platform siemens syngo.via - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
food and drug administration (fda)  (Beratung GmbH)
90
Beratung GmbH food and drug administration (fda)
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Food And Drug Administration (Fda), supplied by Beratung GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration++fda+/10__1007_slash_s12312___020___00834___8-25-42-46
Average 90 stars, based on 1 article reviews
food and drug administration (fda) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
food and drug administration (fda)  (AAFCO Inc)
90
AAFCO Inc food and drug administration (fda)
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Food And Drug Administration (Fda), supplied by AAFCO Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration++fda+/10__2478_slash_aoas___2024___0065-52-10-13
Average 90 stars, based on 1 article reviews
food and drug administration (fda) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
american food and drug administration (fda)  (Kemper GmbH)
90
Kemper GmbH american food and drug administration (fda)
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
American Food And Drug Administration (Fda), supplied by Kemper GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/american+food+and+drug+administration++fda+/pm16919845-118-8-22
Average 90 stars, based on 1 article reviews
american food and drug administration (fda) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
drug administration fda  (Bristol Myers)
86
Bristol Myers drug administration fda
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Drug Administration Fda, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/administration+drug+fda/10__3390_slash_inorganics13070246-63-22-32
Average 86 stars, based on 1 article reviews
drug administration fda - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
food and drug administration (fda) cleared class ii medical device  (ActiGraph llc)
90
ActiGraph llc food and drug administration (fda) cleared class ii medical device
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Food And Drug Administration (Fda) Cleared Class Ii Medical Device, supplied by ActiGraph llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration++fda++cleared+class+ii+medical+device/pm38460544-48-8-16
Average 90 stars, based on 1 article reviews
food and drug administration (fda) cleared class ii medical device - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
compound entity libraries of fda-approved drugs  (ApexBio)
90
ApexBio compound entity libraries of fda-approved drugs
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Compound Entity Libraries Of Fda Approved Drugs, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/compound+entity+libraries+fda++food+drug+administration++approved+drugs/pm38084960-85-5-0
Average 90 stars, based on 1 article reviews
compound entity libraries of fda-approved drugs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
us food and drug administration (fda)  (Informa UK Limited)
90
Informa UK Limited us food and drug administration (fda)
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Us Food And Drug Administration (Fda), supplied by Informa UK Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/us+food+and+drug+administration++fda+/10__1080_slash_01490451__2019__1605427-28-27-1
Average 90 stars, based on 1 article reviews
us food and drug administration (fda) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
food and drug administration (fda)  (Schattauer GmbH)
90
Schattauer GmbH food and drug administration (fda)
Axial T1 weighted MRI (left), 2-[ 18 F]FDG <t>PET</t> (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using <t>(MI</t> <t>Neurology,</t> Siemens) displayed in Z-scores with color scale shown.
Food And Drug Administration (Fda), supplied by Schattauer GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drug+administration+fda+approval/food+and+drug+administration++fda+/10__3414_slash_me16___01___0082-122-22-16
Average 90 stars, based on 1 article reviews
food and drug administration (fda) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Axial T1 weighted MRI (left), 2-[ 18 F]FDG PET (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using (MI Neurology, Siemens) displayed in Z-scores with color scale shown.

Journal: PLoS ONE

Article Title: Hybrid 2-[ 18 F] FDG PET/MRI in premanifest Huntington’s disease gene-expansion carriers: The significance of partial volume correction

doi: 10.1371/journal.pone.0252683

Figure Lengend Snippet: Axial T1 weighted MRI (left), 2-[ 18 F]FDG PET (center) and statistical analysis (right) at the same level in standard anatomical space in two HD gene-expansion carriers (A, B), and a healthy control for comparison (C). Both patients and control had normal MRI. Patient A. 2-[ 18 F]FDG PET SUVR is moderately abnormal with symmetrically decreased metabolism in the Striata (red arrows). Possibly compensatory increased metabolism in the left thalamus (white arrow). CAP S score 1,04. Patient B. 2-[ 18 F]FDG PET SUVR show possibly abnormal metabolism with the impression of slight striatal metabolic reduction (red arrows) compared to the cortex although within normal range in the statistical map. CAP S score 0.91. The figure shows the range of abnormal 2-[ 18 F]FDG PET uptake in patients with high CAP S scores. Note the enlargement of the third ventricle in patient A (orange arrow), that appear as a spurious SPM correlation . The statistical maps (right) compare regional activity without PVC normalized to cerebellar activity to a group of age matched controls using (MI Neurology, Siemens) displayed in Z-scores with color scale shown.

Article Snippet: Furthermore, each 2-[ 18 F]FDG PET were evaluated blinded to diagnosis by subject specific voxel-based analysis comparing regional activity normalized to cerebellar activity with age matched healthy subjects on an individual basis using a standard clinical PET platform (Siemens Syngo.via, MI Neurology, Database (VE20A)).

Techniques: Control, Comparison, Activity Assay